stds-stis-hiv-aids-2017-keynote

9 / 9

Virology research J 2017 Vol 1 Issue 2
Page 28
Notes:
July 26-27, 2017 | Vancouver, Canada
WORLD CONFERENCE ON STDs, STIs & HIV/AIDS
alliedacademies
Development of efficacious vaccine to prevent HIV
infection has been one of major tasks in the last three
decades. We report here an evaluation of the safety and the
immunogenicity of a genetically modified and killed whole-
HIV-1 vaccine designated as SAV001. HIV-1 Clade B NL4-3 was
genetically modified by deleting the nef and vpu genes and
substituted the coding sequence for the Env signal peptide
with that of honeybee melittin signal peptide in order to
generate a replication efficient and attenuated HIV-1. This
genetically modified virus (gmHIV-1NL4-3) was propagated
in the human T cell line, A3.01, followed by virus purification
and inactivation by aldrithiol-2 and γ-irradiation. Thirty-three
HIV-1 positive volunteers receiving cART were recruited for
this observer-blinded, placebo-controlled phase I human
clinical trial to assess the safety and immunogenicity. The
humoral immune responses were assessed by standard
antibody ELISA and by neutralization assay of HIV-1. We found
SAV001 was well tolerated with no serious adverse events.
HIV-1NL4-3 specific PCR showed no evidence of vaccine virus
replication in vitro and in the participants receiving SAV001
vaccine. Furthermore, SAV001 with adjuvant significantly
increased the pre-existing antibody response to HIV-1
proteins. Antibodies in the plasma from these vaccinations
were also found to recognize HIV-1 envelope protein on the
surface of infected cells as well as showed an enhancement
of broadly neutralizing antibodies inhibiting tier I and II of
HIV-1 A, B, and D subtypes. Our results indicate that the
killed whole-HIV vaccine is completely safe and may trigger
appropriate immune responses to prevent HIV infection.
This killed whole-HIV vaccine strategy may pave the way to
develop an effective HIV vaccine.
Speaker Biography
C Yong Kang, PhD, DSc, FRSC, is a Molecular Virologist and Professor of Virology in the
Department of Microbiology and Immunology, Schulich School of Medicine and Den-
tistry at the University of Western Ontario in Canada (1992-Present). He carried out
his Postgraduate studies at McMaster University where he received a PhD in Virology
under the supervision of Professor Ludvik Prevec (1968-1971) and his Post-doctoral
training under Professor Howard Temin at the University of Wisconsin-Madison (1971-
1974). He went on to serve as a Professor of Virology in the Department of Microbi-
ology at the University of Texas, Southwestern Medical School in Dallas, Texas (1974-
1982), Professor and Chairman of the Department of Microbiology and Immunology
at the University of Ottawa, Faculty of Medicine (1982-1992), and Dean of Science at
the University of Western Ontario (1992-1999). He has received numerous prizes such
as the Award of Excellence of the University of Ottawa (1991), Gold Medal for Ilchun
Lecture (1998), Ho-Am Prize in Medicine (1999), the Order of Korea in Science and
Technology (2002), the McMaster University Distinguished Alumni Award for 2007, the
Lifetime Achievement Award from University of Western Ontario (2009), the Queen
Elizabeth II Diamond Jubilee Medal (2012), selected as a Korean-Canadian Diaspora
to Canadian Society by Canadian Government (2013) and the Scientist of the Year
Award from the Korean Federation of Science and Technology (2013). Dr. Kang was
elected as a Life-time Fellow of the Royal Society of Canada Academy of Science (1993)
and an elected Life-time Member of the Korean Academy of Science and Technology
(1997). He continues to serve as a Grant Selection Committee Member for various fed-
eral granting agencies in Canada and the United States. He is a member of the Board
of Directors of numerous research institutions and foundations. He also serves as a
Reviewer for the Journal of Virology, Journal of Infectious Diseases, Virus Research,
Virology, Journal of Biological Chemistry, Journal of Human Virology and Retrovirology,
and Canadian Medical Association Journal.
e:
C Yong Kang
The University of Western Ontario, Canada
Genetically modified and killed whole-HIV vaccine is safe and stimulates anti-HIV
antibody responses in human